Evaxion Biotech Announces Pricing Of $15M Public Offering Of 3.750M ADS At $4.00/ADS
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech has announced the pricing of its public offering, aiming to raise $15 million through the sale of 3.750 million American Depositary Shares (ADS) at a price of $4.00 per ADS.
February 01, 2024 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Evaxion Biotech's public offering of 3.750 million ADS at $4.00 each aims to raise $15 million.
Public offerings often lead to short-term downward pressure on a company's stock price due to the dilution of existing shares. Given the specifics of the offering, it's likely that EVAX's stock might experience a decrease in the short term as the market absorbs the additional shares.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100